Do statins prevent or promote cancer?

Current Oncology

Volumn 15, Issue 2, 2008, Pages 6-7

  Goldstein, Mark R ^a   Mascitelli, Luca ^b   Pezzetta, Francesca ^c  

^a Fountain Medical Court Bonita   (United States)

^b Servizio Sanitario   (Italy)

^c Ospedale Civile di Tolmezzo   (Italy)

Author keywords

Elderly; Regulatory T cells; Statins

Indexed keywords

ATORVASTATIN; BCG VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROTIC PLAQUE; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYSTECTOMY; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; GERIATRIC PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; LETTER; LOW DRUG DOSE; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SOLID TUMOR;

EID: 54349100271     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v15i2.235     Document Type: Letter

References (20)

1. Takahashi HK, Nishibori M. The antitumour activities of statins. Curr Oncol 2007;14:246-7.
2. + T cells. Atherosclerosis 2007; [Epub ahead of print].
3. Goronzy JJ, Weyand CM. Immunomppression in athero-sclerosis: mobilizing the opposition within. Circulation 2006; 114:1901-4.
4. + regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A 2007;104:19446-51.
5. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007:1117:1167-74.
6. Yikirevich E, Resnick MB. Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 2007;25:2506-8.
7. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin bids. J Am Coll Cardiol 2007;50:409-18.
8. Shepherd J, Blauw GJ, Murphy MB, et al. on behalf of the PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) study group. Pravastatin in elderly individuals risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
9. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001; 134:931-40.
10. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK on behalf of the Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007;147:1-9.
11. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-9.
12. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM on behalf of the West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-86.
13. Hoffmann P, Roumeguère T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 2006;355:2705-7.
14. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007;211:144-56.
15. Winer EP, Harris JR, Smith BL, D'Alessandro HA, Brachtel ER Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. N Engl Med 2007;357:1640-8.
16. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80.
17. +CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405.
18. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43:2142-6.
19. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med 2006;166:1938-42.
20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel m) final report. Circulation 2002;106:3143-421.